Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients.
Vachon ML, Factor SH, Branch AD, Fiel MI, Rodriguez-Torres M, Bräu N, Sterling RK, Slim J, Talal AH, Dieterich DT, Sulkowski MS. Vachon ML, et al. Among authors: slim j. J Hepatol. 2011 Jan;54(1):41-7. doi: 10.1016/j.jhep.2010.06.025. Epub 2010 Aug 21. J Hepatol. 2011. PMID: 20974502 Free PMC article. Clinical Trial.
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators. Sulkowski M, et al. Among authors: slim j. Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12. Lancet Infect Dis. 2013. PMID: 23768747 Clinical Trial.
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Schnell G, Pilot-Matias T, Tripathi R, Da Silva-Tillmann B, McGovern B, Campbell AL, Podsadecki T. Sulkowski MS, et al. Among authors: slim j. JAMA. 2015 Mar 24-31;313(12):1223-31. doi: 10.1001/jama.2015.1328. JAMA. 2015. PMID: 25706092 Clinical Trial.
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.
Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M. Rockstroh JK, et al. Among authors: slim j. Clin Infect Dis. 2018 Sep 14;67(7):1010-1017. doi: 10.1093/cid/ciy220. Clin Infect Dis. 2018. PMID: 29566246 Free PMC article. Clinical Trial.
Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.
Eron JJ, Lalezari J, Slim J, Gathe J, Ruane PJ, Wang C, Elion R, Blick G, Khatri A, Hu YB, Gibbons K, Fredrick L, Co M, D'Amico R, Da Silva-Tillmann B, Trinh R, Sulkowski MS. Eron JJ, et al. Among authors: slim j. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19500. doi: 10.7448/IAS.17.4.19500. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394009 Free PMC article.
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
Youle M, Staszweski S, Clotet B, Arribas JR, Blaxhult A, Carosi G, Dejesus E, Di Perri G, Estrada V, Fisher M, Kovacs C, Kulasegaram R, Lazzarin A, Marriott D, Muñoz L, Reynes J, Shalit P, Slim J, Tsoukas C, Vaccaro A, Vera J. Youle M, et al. Among authors: slim j. HIV Clin Trials. 2006 Mar-Apr;7(2):86-96. doi: 10.1310/2xvk-pbgl-735n-wh72. HIV Clin Trials. 2006. PMID: 16798623
173 results